News - 02 Dec `20Vitiligo International Symposium and Patient Conference 2020

New

Virtual but real! The 2020 Vitiligo International Patient Organizations Conference (VIPOC) will be held virtually on Friday, December 4, 2020, followed by Vitiligo International Symposium (VIS) on Saturday and Sunday, Dec. 5-6, 2020.

December 4, 2020

VIPOC conference for patient leaders around the world to increase vitiligo advocacy and knowledge.

DETAILS & FREE REGISTRATION

December 5, 2020

Held every two years, the Vitiligo International Symposium (VIS) is a flagship conference on vitiligo research and clinical management. Traditionally, the VIS consists of informative podium sessions on a range of scientific issues from around the world, combined with clinical reports featuring proven techniques and novel observations, and additional workshops. 

6:00 AM – 7:00 AM Poster session: Attendees will go on their own to view and chat with presenters on the iPosters website.
7:00 AM – 7:30 AM Virtual Waiting Room Opens
7:30 AM – 7:40 AM Welcome Message from Chairs Davinder Parsad, MD & Iltefat Hamzavi, MD
7:40 AM – 8:00 AM GENETIC AND ENVIRONMENTAL CORRELATES OF VITILIGO. RICHARD A. SPRITZ, MD
8:00 AM – 8:10 AM Prevalence of Psychosocial Comorbidities in Vitiligo: A Systematic Literature Review. Khaled Ezzedine, MD, PhD
8:10 AM – 8:20 AM Comparative Study of Safety and Efficacy of Oral Betamethasone Pulse Therapy and Azathioprine in Vitiligo. Mahajabeen Saheb Patel Madarkar, MD
8:20 AM – 8:30 AM Effects of Adding PRP to Microneedling Plus 5-Fluorouracil Therapy in Acral Vitiligo: A Split-Body Randomized Trial. Pankhuri Dudani, MBBS
8:30 AM – 8:50 AM VITILIGO AND COMORBIDITY: A COMPREHENSIVE REVIEW. JUNG ME BAE, MD, PHD
8:50 AM – 9:00 AM Autologous Non-cultured, Non-trypsinized Melanocyte-Keratinocyte Graft Homogenized in Plasma Gel Followed by Narrow-Band Ultraviolet B Therapy for Stable Vitiligo: A Novel Technique. Lamia Elgarhy, MD
9:00 AM – 9:10 AM Donor to Recipient Ratios in the Surgical Treatment of Vitiligo and Piebaldism: A Systematic Review. Vidhya Shankar Narayan, MD
9:10 AM – 9:20 AM Patient Stories, Data and Demo – MyVitiligoTeam. (Patient Social Network). Eric Peacock, Co-Founder and CEO
9:20 AM – 9:40 AM Poster Q&A Sessions #1
9:40 AM – 10:00 AM ADVANCES IN IMMUNE MECHANISMS OF VITILIGO. JOHN E. HARRIS, MD, PHD
10:00 AM – 10:10 AM Effects of Ruxolitinib Cream on Affected Body Areas in Patients with Vitiligo: Subgroup Analysis from a 52-Week, Randomized, Double-Blind Trial. Pearl Grimes, MD
10:10 AM – 10: 20 AM Influencing Factors on the Patient Global Assessment Score for Vitiligo Severity. Nanja van Geel, MD, PhD
10:20 AM – 10:30 AM Pilot Network Model for Automated Vitiligo Lesion Segmentation: Promise and Challenges. Jesslyn Alyce Magee, MS
10:30 AM – 10:50 AM VITILIGO: LOOKING AT THE MEMORY T CELL RESPONSE. JULIEN SENESCHAL, MD, PHD
10:50 AM – 11:10 AM Poster Q&A Sessions #2
11:10 AM – 11:20 AM Wrap up and summary of day. Davinder Parsad, MD & Iltefat Hamzavi, MD
11:20 AM – 1:00 PM Poster session: Attendees will go on their own to view and chat with presenters on the iPosters website.

December 6, 2020

6:00 AM – 7:00 AM Poster session: Attendees will go on their own to view and chat with presenters on the iPosters website.N/A
7:00 AM – 7:30 AM Virtual Waiting Room Opens
7:30 AM – 7:40 AM Welcome Back Message from Chairs Davinder Parsad, MD & Iltefat Hamzavi, MD
7:40 AM – 8:00 AM INTERNATIONAL COLLABORATIVE PROJECT TO STANDARDIZE THE ASSESSMENT AND MONITORING OF VITILIGO IN CLINICAL TRIALS, REGISTRIES AND CLINICAL PRACTICE. NANJA VAN GEEL, MD, PHD
8:00 AM – 8:10 AM Analysis of 24-Week Response to Ruxolitinib Cream for the Treatment of Vitiligo Based on Patient Demographics and Clinical Characteristics. Iltefat H. Hamzavi, MD, FAAD
8:10 AM – 8:20 AM An Open-Label Pilot Study of Abatacept (CTLA4-Ig) for the Treatment of Nonsegmental Vitiligo. Victor Huang, MD
8:20 AM – 8:30 AM Analysis of Matched Skin and Gut Microbiome of Vitiligo Patients Reveals Dysbiosis in Lesional Skin: Association with Mitochondrial Damage and Changes in Immune Function. Meri K. Tulic, PhD
8:30 AM- 8:50 AM ADVANCES IN TREATMENT OF VITILIGO WITH JAK INHIBITORS. AMIT G. PANDYA, MD
8:50 AM – 9:00 AM Risk Factors of Infection Post Non-cultured Melanocyte Keratinocyte Transplantation for Vitiligo. Saad Altalhb, MBBS
9:00 AM – 9:10 AM Survey Investigating the Prevalence of Vitiligo and Vitiligo Signs among Adults in Europe, Japan, and the United States. John E. Harris, MD, PhD
9:10 AM – 9:20 AM An Identification of Potential Therapeutics for Vitiligo by Mass Screening for 1,732 Medicines in Korean National Health Insurance Database. Jung Me Bae, MD, PhD
9:20 AM- 9:40 AM Poster Q&A Sessions #3
9:40 AM – 10:00 AM RECENT ADVANCES IN THE SURGICAL MANAGEMENT OF VITILIGO. DAVINDER PARSAD, MD
10:00 AM – 10:10 AM A Comparative Pilot Study of Dipstick versus Open-Spray Cryotherapy Techniques as Depigmentation Treatments for Vitiligo. Haitham M. Saleh, Msc
10:10 AM – 10:20 AM Therapeutic Response Biomarkers for Vitiligo Patients on Narrow Band Uvb and Topical Tacrolimus Combination Therapy. Youwen Zhou, MD, PhD
10:20 AM – 10:30 AM Vitiligo and Psychological Comorbidities: A Retrospective Analysis in an Urban Population. Simone Nichole Boeckmann Montgomery, BA
10:30 AM – 10:50 AM PHOTOTHERAPY FOR VITILIGO: HOW TO OPTIMIZE AND WHAT THE FUTURE HOLDS. ILTEFAT H. HAMZAVI, MD
10:50 AM – 11:10 AM Poster Q&A Sessions #4
11:10 AM – 11:20 AM Wrap up and summary of day Davinder Parsad, MD & Iltefat Hamzavi, MD
11:20 AM – 1:00 PM Poster session: Attendees will go on their own to view and chat with presenters on the iPosters website.
info@vis2020.org
 
DETAILS & FREE REGISTRATION

The times in the tables above are USA Eastern Time. The following is provided to help you convert it into your location time.

  • Paris, France: +6 hours
  • New Delhi, India: +10.5 hours
  • Beijing, China: +13 hours
  • Seoul, Korea: + 14 hours



Vitiligo patient conference 2020    Vitiligo International Symposium 2020

 

      FAQOther Questions

      • Who is prone to vitiligo?

        Scientists know that some people are genetically predisposed to a specific group of autoimmune diseases – including generalized vitiligo – but do not know who and why.It doesn’t...

      • How to get insurance coverage for vitiligo treatments?

        Most of health insurance companies will initially reject claims for vitiligo doctor visits or phototherapy treatments but with enough efforts you can have a substantial part of ...

      • What tests should be done?

        A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...